Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer.
Giulia PetroniAitziber BuqueTakahiro YamazakiNorma BloyMaurizio Di LibertoSelina Chen-KiangSylvia C FormentiLorenzo GalluzziPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Our preclinical findings demonstrate that radiotherapy delivered before CDK4/6 inhibitors mediates superior antineoplastic effects compared with alternative treatment schedules, calling into question the design of clinical trials administering CDK4/6 inhibitors before radiotherapy in women with ER+ breast cancer.